

## Libtayo® (cemiplimab-rwlc) (Intravenous)

Document Number: IC-0398

Last Review Date: 03/02/2023

Date of Origin: 10/30/2018

Dates Reviewed: 11/2018, 03/2019, 06/2019, 09/2019, 12/2019, 03/2020, 6/2020, 12/2020, 03/2021, 06/2021, 09/2021, 12/2021, 03/2022, 06/2022, 09/2022, 12/2022, 03/2023

### I. Length of Authorization

Coverage will be provided for 6 months and may be renewed.

### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [NDC Unit]:

- Libtayo 350 mg/7 mL single-dose vial: 1 vial per 21 days

#### B. Max Units (per dose and over time) [HCPCS Unit]:

- 350 billable units (350 mg) every 21 days

### III. Initial Approval Criteria <sup>1</sup>

Coverage is provided for the following conditions:

- Patient is at least 18 years of age; **AND**

#### Universal Criteria <sup>1</sup>

- Patient has not received previous therapy with a programmed death (PD-1/PD-L1)-directed therapy (e.g., avelumab, pembrolizumab, atezolizumab, durvalumab, nivolumab, dostarlimab, nivolumab/relatlimab-rmbw, etc.), unless otherwise specified; **AND**

#### Cutaneous Squamous Cell Carcinoma (cSCC) † ‡ <sup>1-5,8</sup>

- Patient has metastatic disease, locally advanced disease, unresectable disease, inoperable or incompletely resected regional disease, new regional disease, or local or regional recurrence; **AND**
- Used as a single agent; **AND**
- Patient is not a candidate for curative surgery or curative radiation therapy

#### Basal Cell Carcinoma (BCC) † ‡ <sup>1,2,6,9</sup>

- Patient has previously been treated with a hedgehog pathway inhibitor (HHI) (e.g., vismodegib, sonidegib, etc.) or is not a candidate for HHI treatment; **AND**

- Used as a single agent; **AND**
  - Patient has locally advanced disease; **OR**
  - Patient has local recurrence and is not a candidate for curative surgery or curative radiation therapy; **OR**
  - Patient has nodal, regional, or metastatic disease

#### **Non-Small Cell Lung Cancer (NSCLC) † ‡ 1,2,7,10**

- Used in combination with platinum-based chemotherapy (e.g., paclitaxel and either carboplatin or cisplatin OR pemetrexed and either carboplatin or cisplatin); **AND**
  - Patient has recurrent, advanced, or metastatic disease; **AND**
    - Used as first-line therapy for one of the following:
      - Patients with a performance status (PS) 0-1 who have tumors that are negative for actionable molecular biomarkers\* and PD-L1 expression <1%
      - Patients with a PS 0-1 who are positive for one of the following molecular biomarkers: EGFR exon 20, KRAS G12C, BRAF V600E, NTRK1/2/3 gene fusion, MET exon 14 skipping, RET rearrangement, or ERBB2 (HER2)
      - PD-L1 expression-positive (PD-L1 ≥1%) tumors, as detected by an FDA or CLIA compliant test❖, that are negative for actionable molecular biomarkers\*; **OR**
    - Used as subsequent therapy for one of the following:
      - Patients with a PS 0-1 who are positive for one of the following molecular mutations and have received prior targeted therapy§: EGFR exon 19 deletion or L858R tumors, EGFR S768I, L861Q, and/or G719X, ALK rearrangement, or ROS1 rearrangement
      - Patients with a PS 0-1 who are positive for one of the following molecular biomarkers: BRAF V600E, NTRK1/2/3 gene fusion, MET exon 14 skipping, or RET rearrangement; **OR**
    - Used as continuation maintenance therapy in patients who have achieved a tumor response or stable disease following initial therapy; **AND**
      - Used in combination with pemetrexed following a first-line cemiplimab/pemetrexed/(carboplatin or cisplatin) regimen for non-squamous cell histology; **OR**
  - Used as a single agent; **AND**
    - Patient has tumors that are negative for actionable molecular biomarkers\* and high PD-L1 expression (Tumor Proportion Score [TPS] ≥ 50%) as determined by an FDA-approved or CLIA compliant test❖; **AND**
      - Patient has recurrent, advanced, or metastatic disease (excluding locoregional recurrence or symptomatic local disease with no evidence of disseminated disease) or mediastinal lymph node recurrence with prior radiation therapy; **AND**

- Used as first-line therapy †; **OR**
- Used as continuation maintenance therapy in patients who achieved a tumor response or stable disease after first-line therapy with cemiplimab-rwlc as monotherapy or as part of combination therapy; **OR**
- o Patient has tumors with PD-L1 expression <1% or ≥1%-49% as detected by an FDA or CLIA compliant test❖; **AND**
  - Patient has recurrent, advanced, or metastatic disease; **AND**
  - Used as continuation maintenance therapy in patients who have achieved a tumor response or stable disease following initial therapy with cemiplimab combination therapy

*\* Note: Actionable molecular genomic biomarkers include EGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET exon 14 skipping mutation, RET rearrangement and ERBB2 (HER2). If there is insufficient tissue to allow testing for all of EGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, and ERBB2 (HER2), repeat biopsy and/or plasma testing should be done. If these are not feasible, treatment is guided by available results and, if unknown, these patients are treated as though they do not have driver oncogenes.*

❖ *If confirmed using an immunotherapy assay-<http://www.fda.gov/companiondiagnostics>*

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Ⓢ Orphan Drug

#### IV. Renewal Criteria <sup>1</sup>

Coverage may be renewed based on the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: severe infusion-related reactions, severe and fatal immune-mediated adverse reactions (e.g., pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, dermatologic adverse reactions, etc.), complications of allogeneic hematopoietic stem cell transplantation (HSCT), etc.; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**

**Non-Small Cell Lung Cancer (continuation maintenance therapy):**

- *Refer to Section III for criteria*

#### V. Dosage/Administration <sup>1</sup>

| Indication | Dose |
|------------|------|
|------------|------|

|                 |                                                                                                  |
|-----------------|--------------------------------------------------------------------------------------------------|
| All Indications | Administer 350 mg intravenously every 3 weeks until disease progression or unacceptable toxicity |
|-----------------|--------------------------------------------------------------------------------------------------|

## VI. Billing Code/Availability Information

### HCPCS Code:

- J9119 – Injection, cemiplimab-rwlc, 1 mg; 1 billable units = 1 mg

### NDC:

- Libtayo 350 mg/7 mL single-dose vial: 61755-0008-xx

## VII. References

1. Libtayo [package insert]. Tarrytown, NY; Regeneron Pharmaceuticals; November 2022. Accessed January 2023.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) cemiplimab-rwlc. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed January 2023.
3. Falchook GS, Leidner R, Stankevich E, et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer. 2016 Nov 15;4:70. doi: 10.1186/s40425-016-0176-3. eCollection 2016.
4. Migden MR, Rischin D, Schmults CD, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.
5. Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020 Feb;21(2):294-305. doi: 10.1016/S1470-2045(19)30728-4. Epub 2020 Jan 14.
6. Lewis KD, Fury MG, Stankevich, et al. Phase II study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HHI) therapy. Annals of Oncology. 2018 Oct 01; Volume 29, Supplement 8,VII440.
7. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021 Feb 13;397(10274):592-604.
8. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Squamous Cell Skin Cancer. Version 2.2022. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN

GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed January 2023.

9. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Basal Cell Skin Cancer. Version 2.2022. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed January 2023.
10. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Non-Small Cell Lung Cancer. Version 1.2023. National Comprehensive Cancer Network, 2023. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed January 2023.
11. Gogishvili M, Melkadze T, Makharadze T, et al. LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). Annals of Oncology, ISSN: 0923-7534, Vol: 32, SUPPLEMENT 5, S1328, SEPTEMBER 01, 2021. DOI10.1016/j.annonc.2021.08.2130.

## Appendix 1 – Covered Diagnosis Codes

| ICD-10 | ICD-10 Description                                                       |
|--------|--------------------------------------------------------------------------|
| C33    | Malignant neoplasm of trachea                                            |
| C34.00 | Malignant neoplasm of unspecified main bronchus                          |
| C34.01 | Malignant neoplasm of right main bronchus                                |
| C34.02 | Malignant neoplasm of left main bronchus                                 |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung           |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung                 |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung                  |
| C34.2  | Malignant neoplasm of middle lobe, bronchus or lung                      |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung           |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung                 |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung                  |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung       |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung        |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung   |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung         |

| ICD-10   | ICD-10 Description                                                              |
|----------|---------------------------------------------------------------------------------|
| C34.92   | Malignant neoplasm of unspecified part of left bronchus or lung                 |
| C44.01   | Basal cell carcinoma of skin of lip                                             |
| C44.02   | Squamous cell carcinoma of skin of lip                                          |
| C44.111  | Basal cell carcinoma of skin of unspecified eyelid, including canthus           |
| C44.1121 | Basal cell carcinoma of skin of right upper eyelid, including canthus           |
| C44.1122 | Basal cell carcinoma of skin of right lower eyelid, including canthus           |
| C44.1191 | Basal cell carcinoma of skin of left upper eyelid, including canthus            |
| C44.1192 | Basal cell carcinoma of skin of left lower eyelid, including canthus            |
| C44.121  | Squamous cell carcinoma of skin of unspecified eyelid, including canthus        |
| C44.1221 | Squamous cell carcinoma of skin of right upper eyelid, including canthus        |
| C44.1222 | Squamous cell carcinoma of skin of right lower eyelid, including canthus        |
| C44.1291 | Squamous cell carcinoma of skin of left upper eyelid, including canthus         |
| C44.1292 | Squamous cell carcinoma of skin of left lower eyelid, including canthus         |
| C44.211  | Basal cell carcinoma of skin of unspecified ear and external auricular canal    |
| C44.212  | Basal cell carcinoma of skin of right ear and external auricular canal          |
| C44.219  | Basal cell carcinoma of skin of left ear and external auricular canal           |
| C44.221  | Squamous cell carcinoma of skin of unspecified ear and external auricular canal |
| C44.222  | Squamous cell carcinoma of skin of right ear and external auricular canal       |
| C44.229  | Squamous cell carcinoma of skin of left ear and external auricular canal        |
| C44.310  | Basal cell carcinoma of skin of unspecified parts of face                       |
| C44.311  | Basal cell carcinoma of skin of nose                                            |
| C44.319  | Basal cell carcinoma of skin of other parts of face                             |
| C44.320  | Squamous cell carcinoma of skin of unspecified parts of face                    |
| C44.321  | Squamous cell carcinoma of skin of nose                                         |
| C44.329  | Squamous cell carcinoma of skin of other parts of face                          |
| C44.41   | Basal cell carcinoma of skin of scalp and neck                                  |
| C44.42   | Squamous cell carcinoma of skin of scalp and neck                               |
| C44.510  | Basal cell carcinoma of anal skin                                               |
| C44.511  | Basal cell carcinoma of skin of breast                                          |
| C44.519  | Basal cell carcinoma of skin of other part of trunk                             |
| C44.520  | Squamous cell carcinoma of anal skin                                            |
| C44.521  | Squamous cell carcinoma of skin of breast                                       |
| C44.529  | Squamous cell carcinoma of skin of other part of trunk                          |
| C44.611  | Basal cell carcinoma of skin of unspecified upper limb, including shoulder      |
| C44.612  | Basal cell carcinoma of skin of right upper limb, including shoulder            |
| C44.619  | Basal cell carcinoma of skin of left upper limb, including shoulder             |
| C44.621  | Squamous cell carcinoma of skin of unspecified upper limb, including shoulder   |
| C44.622  | Squamous cell carcinoma of skin of right upper limb, including shoulder         |



| ICD-10  | ICD-10 Description                                                       |
|---------|--------------------------------------------------------------------------|
| C44.629 | Squamous cell carcinoma of skin of left upper limb, including shoulder   |
| C44.711 | Basal cell carcinoma of skin of unspecified lower limb, including hip    |
| C44.712 | Basal cell carcinoma of skin of right lower limb, including hip          |
| C44.719 | Basal cell carcinoma of skin of left lower limb, including hip           |
| C44.721 | Squamous cell carcinoma of skin of unspecified lower limb, including hip |
| C44.722 | Squamous cell carcinoma of skin of right lower limb, including hip       |
| C44.729 | Squamous cell carcinoma of skin of left lower limb, including hip        |
| C44.81  | Basal cell carcinoma of overlapping sites of skin                        |
| C44.82  | Squamous cell carcinoma of overlapping sites of skin                     |
| C44.91  | Basal cell carcinoma of skin, unspecified                                |
| C44.92  | Squamous cell carcinoma of skin, unspecified                             |
| Z85.118 | Personal history of other malignant neoplasm of bronchus and lung        |

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at:

<https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

| Medicare Part B Administrative Contractor (MAC) Jurisdictions |                                                                                             |                                                   |
|---------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------|
| Jurisdiction                                                  | Applicable State/US Territory                                                               | Contractor                                        |
| E (1)                                                         | CA, HI, NV, AS, GU, CNMI                                                                    | Noridian Healthcare Solutions, LLC                |
| F (2 & 3)                                                     | AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ                                                      | Noridian Healthcare Solutions, LLC                |
| 5                                                             | KS, NE, IA, MO                                                                              | Wisconsin Physicians Service Insurance Corp (WPS) |
| 6                                                             | MN, WI, IL                                                                                  | National Government Services, Inc. (NGS)          |
| H (4 & 7)                                                     | LA, AR, MS, TX, OK, CO, NM                                                                  | Novitas Solutions, Inc.                           |
| 8                                                             | MI, IN                                                                                      | Wisconsin Physicians Service Insurance Corp (WPS) |
| N (9)                                                         | FL, PR, VI                                                                                  | First Coast Service Options, Inc.                 |
| J (10)                                                        | TN, GA, AL                                                                                  | Palmetto GBA, LLC                                 |
| M (11)                                                        | NC, SC, WV, VA (excluding below)                                                            | Palmetto GBA, LLC                                 |
| L (12)                                                        | DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA) | Novitas Solutions, Inc.                           |
| K (13 & 14)                                                   | NY, CT, MA, RI, VT, ME, NH                                                                  | National Government Services, Inc. (NGS)          |
| 15                                                            | KY, OH                                                                                      | CGS Administrators, LLC                           |

## Nondiscrimination & Language Access Policy

Aspirus Health Plan, Inc. complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, sexual orientation, or gender identity. We do not exclude people or treat them differently because of race, color, national origin, age, disability, sex, sexual orientation, or gender identity.

We will:

Provide free aids and services to people with disabilities to communicate effectively with us, such as:

- Qualified sign language interpreters
- Written information in other formats (large print, audio, accessible electronic formats, other formats)

Provide free language services to people whose primary language is not English, such as:

- Qualified interpreters
- Information written in other languages

If you need these services, contact us at the phone number shown on the inside cover of this contract, your id card, or aspirushealthplan.com.

If you believe that we have failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, sex, sexual orientation, or gender identity, you can file a grievance with:

Nondiscrimination Grievance Coordinator  
Aspirus Health Plan, Inc.  
PO Box 1062  
Minneapolis, MN 55440  
Phone: 1.866.631.5404 (TTY: 711)  
Fax: 763.847.4010  
Email: customerservice@aspirushealthplan.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Nondiscrimination Grievance Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at:

U.S. Department of Health and Human Services  
200 Independence Avenue, SW  
Room 509F, HHH Building  
Washington, D.C. 20201  
1-800-368-1019, 800-537-7697 (TDD)

Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

## Language Assistance Services

**Albanian:** KUJDES: Nëse flitni shqip, për ju ka në dispozicion shërbime të asistencës gjuhësore, pa pagesë. Telefononi në 1.866.631.5404 (TTY: 711).

**Arabic:** تنبيه: إذا كنت تتحدث اللغة العربية، فإن خدمات المساعدة اللغوية متاحة لك مجاناً. اتصل بن اعلی رقم الهاتف 1.866.631.5404 (رقم هاتف الصم والبك : 711)

**French:** ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelezle 1.866.631.5404 (ATS : 711).

**German:** ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1.866.631.5404 (TTY: 711).

**Hindi:** \_यान द\_ : य\_द आप िहंदी बोलते ह\_ तो आपके िलए मु\_त म\_ भाषा सहायता सेवाएं उपल\_ध ह\_। 1.866.631.5404 (TTY: 711) पर कॉल कर\_।

**Hmong:** LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 1.866.631.5404 (TTY: 711).

**Korean:** 주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1.866.631.5404 (TTY: 711)번으로 전화해 주십시오.

**Polish:** UWAGA: Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 1.866.631.5404 (TTY: 711).

**Russian:** ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1.866.631.5404 (телетайп: 711).

**Spanish:** ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1.866.631.5404 (TTY: 711).

**Tagalog:** PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nangwalang bayad. Tumawag sa 1.866.631.5404 (TTY: 711)

**Traditional Chinese:** 注意: 如果您使用繁體中文, 您可以免費獲得語言援助服務。請致電 1.866.631.5404 (TTY: 711)。

**Vietnamese:** CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1.866.631.5404 (TTY: 711).

**Pennsylvania Dutch:** Wann du Deitsch (Pennsylvania German / Dutch) schwetzscht, kannscht du mitaus Koschte ebbergricke, ass dihr helft mit die englisch Schprooch. Ruf selli Nummer uff: Call 1.866.631.5404 (TTY: 711).

**Lao:** ໄປດຊາຍ: ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສັຽຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທ 1.866.631.5404 (TTY: 711).